This study is for people with certain blood cancers, including Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, and Diffuse Large B-cell Lymphoma. It aims to gather more information on the long-term safety and effectiveness of a drug called ibrutinib. You could join if you are already taking ibrutinib in another study that has finished, have been on it for at least 6 months, and are still benefiting from the treatment. The study will look at any side effects you experience. The current status of this study is unclear, and it plans to enroll around 700 participants.

Study design

This is an open-label study, meaning you and your doctors will know you are receiving ibrutinib. It is designed to collect long-term data and provide continued access to ibrutinib for participants already in other studies.

What's involved

You would continue to take ibrutinib orally once daily at your current dose. This will continue until your doctor decides you are no longer benefiting, you withdraw, or other options for getting ibrutinib become available.

Compensation

Not stated in the trial record.

Follow-up

Safety will be monitored for up to 30 days after your last dose of ibrutinib, or until you start another cancer treatment, whichever comes first.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.